Plain-English translation of NCT07611110 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new radioactive medication called AZD2265 in patients with advanced prostate cancer that has continued to grow despite previous treatments. The medication uses a radioactive element (actinium-225) attached to a targeting agent that seeks out cancer cells. Researchers want to see if this treatment works better and is safer than the standard treatment options currently available.
Many patients with advanced prostate cancer eventually stop responding to existing treatments, and their cancer continues to spread. This trial exists to find out whether this new radioactive approach can help patients whose cancer has become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either receive the new medication (AZD2265) or one of the standard treatment options, depending on what your doctor recommends. You will receive your assigned treatment until your cancer progresses, you experience unacceptable side effects, or another stopping point is reached. Throughout and after treatment, you will have regular imaging scans (CT, MRI, or bone scans) to check how your cancer is responding, and you will be followed for survival for the duration of the study.
AI-generated summary from trial data · Oct 3, 2026 · Not medical advice
United States